Figure 4. Risk of HIV superinfection and drug resistance associated with HIV-positive organ donors.
Patients on first-line ART regimens, infected with R5 tropic virus, who have potential for protease inhibitor ritonavir-sparing ART regimens, and who have higher CD4+ T-cell counts are at lower risk of causing HIV superinfection or spreading drug resistance.